PF-Atlas › Clinical Trials › NCT02456103
Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
Ataluren · Phase 3
Registry ID
NCT02456103
Phase
Phase 3
Status
Terminated
Drug / intervention
Ataluren
Sponsor
PTC Therapeutics
Start
2015-08-31
Enrollment
246
Locations
70
About this trial
This is an open-label extension study for participants who completed a Phase 3, placebo-controlled study of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02456103 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.